presentation skuldtech horizon

Skuldtech_infos

From Biomarker discovery to personalized medicine

Skuldtech is a French biotechnology company located in Montpellier (south of France), and specialized in the discovery of new molecular
biomarkers for diagnostic and therapeutic purposes. To reach its objectives, the company has developed and continually refined a
technology platform for identifying biomarkers associating new high-throughput technologies, and proprietary bioinformatic and
biostatistical tools. Its business model is based on two main business lines: 1) Innovative Diagnostics and Companion Diagnostics (CDx)
development for personalized medicine applications; 2) Services focused on genomic biomarkers discovery and pharmacogenomic studies.

Technologies and expertise

Skuldtech has developed its technology platform for RNA and DNA analysis based on new high-throughput sequencing techniques (NGS)
and biomolecular technologies (qRT-PCR…). In order to process and analyze the millions of pieces of the generated data, the company
uses its proprietary tools and database, as well as biostatistical tools specifically developed for studying the data in question, and designed
for the integrated analysis of biological information. In particular, Skuldtech leverages over 12 years acquiring expertise examining and
interpreting this type of data.

Product Pipeline

Skuldtech is involved in several clinical trials phases for proprietary companion diagnostic and patient stratification: 1) A companion
diagnostic associated with AB Science’s masitinib used for treating pancreatic cancer (the Marketing Authorization Application has already
been filed with regulatory authorities) will soon be developed to identify patients most likely to benefit from this new treatment; 2) A
patient stratification diagnostic in Chronic Myelomonocytic Leukemia – CMML (now in phase II trials)…

Observed needs for greater therapeutic efficiency

Skuldtech’s diagnostics positioning meets the increasing need to improve the therapeutic efficiency of patient treatments. In the United
States in 2005, it was observed that 3 million prescriptions, representing an amount of 3.5 billion dollars, could be considered as
inappropriate or ineffective (PriceWaterHouseCoopers “Personalized Medicine: The Emerging Pharmacogenomics Revolution”, 2005).

Potential market

According to different sources*, molecular diagnostics associated to drugs are expected to grow to 25%-30% within the next 5 years. 10%
to 20% of new drugs are expected to have a companion diagnostic in 2025. Moreover, regarding Skuldtech services positioning, the latest
FDA (feb.2011) and EMEA (dec.2010) guidelines systematically include pharmacogenomic analyses in clinical trials. Proof-of-concept for
this approach has already been demonstrated in various cases, notably making it possible to adapt clinical pharmacology and to favor, even
to enable, the release of drugs on the market (Warfarine, Clopidogrel, Abracavir…). Health Authorities position will enhance dramatically
services for pharmacogenomics studies. *BCC Research, Business Insight, Espicom Business Intelligence, Biomerieux, Bayer Diagnostics, Nature Biotechnologies, PwC.
R&D programs generating industrial property and future sales
Skuldtech is labeled by the French ministry of Research and Innovation for its R&D programs and technologies. Today, the company
meets increasing demands for its services while continuing to invest in R&D programs that generate value and industrial property. The
upcoming companion diagnostic tests will be released on the market starting in 2013 and are expected to generated 79 M€ in 2017.

Shareholders and management team

Skuldtech capital is today shared by founders (47.2%), scientific board (2.8%), and private and professional investors (50%). The
management team is composed by founders:
) Didier RITTER, CEO. Master in Molecular Biology and Master of Business Administration Montpellier. Consultant (Bio2R)
) David PIQUEMAL, CSO. PhD in Biology. Expert in techniques for analyzing gene expression changes.
) Philippe OUTREBON, CFO. Master in Mathematics. Company founder, consultant (Ernst & Young).

Why is Skuldtech seeking funds?

Skuldtech is seeking financing to:
A – Fund R&D programs for personalized medicine solutions expected to generate an estimated 95 M€ in 2017.
B – Hire staff and invest to meet the increasing demand for its services in genomics and pharmacogenomics.

source: site de skuldtech --> corporate --> investor--> executive summary